Nanotechnologies in glycoproteomics

Hu Zhao, Yaojun Li, Ye Hu

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Protein glycosylation, as an important post-Translational modification, is implicated in a number of ailments. Applying proteomic approaches, including mass spectrometry (MS) analyses that have played a significant role in biomarker detection and early diagnosis of diseases, to the study of glycoproteins or glycopeptides will facilitate a deeper understanding of many physiological functions and biological pathways involved in cancer, inflammatory and degenerative diseases. The abundance of glycopeptides and their ionization potential are relatively lower compared to those of non-glycopeptides; therefore, sample enrichment is necessary for glycopeptides prior to MS analysis. The application of nanotechnology in the past decade has been rapidly penetrating into many diverse scientific research disciplines. Particularly in what we now refer to as the "glycoproteomics area", nanotechnologies have enabled enhanced sensitivity and specificity of glycopeptide detection in complex biological fluids, which are critical for disease diagnosis and monitoring. In this review, we highlight some recent studies that combine the capabilities of specific nanotechnologies with the comprehensive features of glycoproteomics. In particular, we focus on the ways in which nanotechnology has facilitated the detection of glycopeptides in complex biological samples and enhanced their characterization by MS, in terms of intensity and resolution. These studies reveal an increasingly important role for nanotechnology in helping to overcome certain technical challenges in biomarker discovery, in general, and glycoproteomics research, in particular.

Original languageEnglish (US)
Article number21
JournalClinical Proteomics
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Nanotechnology
Glycopeptides
Mass spectrometry
Mass Spectrometry
Biomarkers
Early Diagnosis
Glycosylation
Ionization potential
Post Translational Protein Processing
Research
Proteomics
Glycoproteins
Sensitivity and Specificity
Fluids
Monitoring
Neoplasms
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

Nanotechnologies in glycoproteomics. / Zhao, Hu; Li, Yaojun; Hu, Ye.

In: Clinical Proteomics, Vol. 11, No. 1, 21, 01.01.2014.

Research output: Contribution to journalReview article

Zhao, Hu ; Li, Yaojun ; Hu, Ye. / Nanotechnologies in glycoproteomics. In: Clinical Proteomics. 2014 ; Vol. 11, No. 1.
@article{2e801225683a4e09b15bfcf14054c4bd,
title = "Nanotechnologies in glycoproteomics",
abstract = "Protein glycosylation, as an important post-Translational modification, is implicated in a number of ailments. Applying proteomic approaches, including mass spectrometry (MS) analyses that have played a significant role in biomarker detection and early diagnosis of diseases, to the study of glycoproteins or glycopeptides will facilitate a deeper understanding of many physiological functions and biological pathways involved in cancer, inflammatory and degenerative diseases. The abundance of glycopeptides and their ionization potential are relatively lower compared to those of non-glycopeptides; therefore, sample enrichment is necessary for glycopeptides prior to MS analysis. The application of nanotechnology in the past decade has been rapidly penetrating into many diverse scientific research disciplines. Particularly in what we now refer to as the {"}glycoproteomics area{"}, nanotechnologies have enabled enhanced sensitivity and specificity of glycopeptide detection in complex biological fluids, which are critical for disease diagnosis and monitoring. In this review, we highlight some recent studies that combine the capabilities of specific nanotechnologies with the comprehensive features of glycoproteomics. In particular, we focus on the ways in which nanotechnology has facilitated the detection of glycopeptides in complex biological samples and enhanced their characterization by MS, in terms of intensity and resolution. These studies reveal an increasingly important role for nanotechnology in helping to overcome certain technical challenges in biomarker discovery, in general, and glycoproteomics research, in particular.",
author = "Hu Zhao and Yaojun Li and Ye Hu",
year = "2014",
month = "1",
day = "1",
doi = "10.1186/1559-0275-11-21",
language = "English (US)",
volume = "11",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Nanotechnologies in glycoproteomics

AU - Zhao, Hu

AU - Li, Yaojun

AU - Hu, Ye

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Protein glycosylation, as an important post-Translational modification, is implicated in a number of ailments. Applying proteomic approaches, including mass spectrometry (MS) analyses that have played a significant role in biomarker detection and early diagnosis of diseases, to the study of glycoproteins or glycopeptides will facilitate a deeper understanding of many physiological functions and biological pathways involved in cancer, inflammatory and degenerative diseases. The abundance of glycopeptides and their ionization potential are relatively lower compared to those of non-glycopeptides; therefore, sample enrichment is necessary for glycopeptides prior to MS analysis. The application of nanotechnology in the past decade has been rapidly penetrating into many diverse scientific research disciplines. Particularly in what we now refer to as the "glycoproteomics area", nanotechnologies have enabled enhanced sensitivity and specificity of glycopeptide detection in complex biological fluids, which are critical for disease diagnosis and monitoring. In this review, we highlight some recent studies that combine the capabilities of specific nanotechnologies with the comprehensive features of glycoproteomics. In particular, we focus on the ways in which nanotechnology has facilitated the detection of glycopeptides in complex biological samples and enhanced their characterization by MS, in terms of intensity and resolution. These studies reveal an increasingly important role for nanotechnology in helping to overcome certain technical challenges in biomarker discovery, in general, and glycoproteomics research, in particular.

AB - Protein glycosylation, as an important post-Translational modification, is implicated in a number of ailments. Applying proteomic approaches, including mass spectrometry (MS) analyses that have played a significant role in biomarker detection and early diagnosis of diseases, to the study of glycoproteins or glycopeptides will facilitate a deeper understanding of many physiological functions and biological pathways involved in cancer, inflammatory and degenerative diseases. The abundance of glycopeptides and their ionization potential are relatively lower compared to those of non-glycopeptides; therefore, sample enrichment is necessary for glycopeptides prior to MS analysis. The application of nanotechnology in the past decade has been rapidly penetrating into many diverse scientific research disciplines. Particularly in what we now refer to as the "glycoproteomics area", nanotechnologies have enabled enhanced sensitivity and specificity of glycopeptide detection in complex biological fluids, which are critical for disease diagnosis and monitoring. In this review, we highlight some recent studies that combine the capabilities of specific nanotechnologies with the comprehensive features of glycoproteomics. In particular, we focus on the ways in which nanotechnology has facilitated the detection of glycopeptides in complex biological samples and enhanced their characterization by MS, in terms of intensity and resolution. These studies reveal an increasingly important role for nanotechnology in helping to overcome certain technical challenges in biomarker discovery, in general, and glycoproteomics research, in particular.

UR - http://www.scopus.com/inward/record.url?scp=84903756544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903756544&partnerID=8YFLogxK

U2 - 10.1186/1559-0275-11-21

DO - 10.1186/1559-0275-11-21

M3 - Review article

VL - 11

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 21

ER -